Acalabrutinib and Rituximab in Previously Untreated Mantle Cell Lymphoma
Status:
Not yet recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
This is a phase II, single-arm, open-label, multicentre study of acalabrutinib and rituximab
for elderly or frail patients with previously untreated mantle cell lymphoma.